Immuron picks new director
Immuron (ASX:IMC) has appointed Stephen Anastasiou as its latest non-executive director.
Anastasiou’s career in the healthcare industry has spanned more than 20 years, focusing on general management, marketing and strategic planning.
He has had roles including management consultant at KPMG Peat Marwick (now KPMG) and a management position at international pharmaceutical company Bristol Myer Squibb.
Anastasiou is currently a director and shareholder of a number of unlisted companies in healthcare and other sectors.
Immuron has developed Travelan, an OTC treatment for travellers’ diarrhoea. In 2011, the company scored a licensing deal for the product with distributor Paladin Labs worth up to $115 million. The company is also developing a treatment for hospital superbug C. difficile.
Immuron shares were trading unchanged at $0.004 as of around 1 pm on Wednesday.
Oxytocin analogue treats chronic abdominal pain
Researchers have developed a new class of oral painkillers to suppress chronic abdominal pain,...
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
